However, about 30% to 40% of patients diagnosed with liver cancer have no significant increase in AFP, and the sensitivity of AFP in early-stage liver cancer is only 30% to 40%, while about 20% to 50% of patients with chronic hepatitis and cirrhosis have elevated AFP. This evidence concerns the gene AFP and chronic hepatitis.